• Test Code: ON001

Test Description

Anyone with personal or family history of Breast Cancer, Ovarian Cancer, or Pancreatic Cancer is recommended to take GCG Women’s Cancer Panel for diagnosis of hereditary Breast & Ovarian Cancer. Not only BRACA1 & BRACA2 genes, GCG Women’s Cancer Panel analyses 13 more genes related to Breast and Ovarian Cancer.

Ordering information

  • Turnaround time: 12 Days
  • Specimen: EDTA 3ml
Specimen requirements
Test Requisition Form

Assay information

  • Target Region: 15 genes (69,299bp)
  • Target enrichment method: Hybridization with oligonucleotide probes
  • Massively parallel sequencing: MiseqDX (150 bp x 2 paired-ends)
  • Reference genome: GRCh37/hg19
  • Gene List: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, NBN, NF1, PALB2, PPM1D, PTEN, RAD51C, STK11, TP53

Result

The test results will be provided according to the designated TAT. Review the sample report to see how the results are structured.

Sample report

Limitations

  • This test is performed by NGS technique. The genes included in the test include the entire exon, but in some areas sequencing may not be sufficiently covered.
  • In addition, if a highly homologous sequence exists, the sequencing of the base may not be accurate, and exonic deletion/duplication, regulatory or deep intronic region, repeat expansion, imprinting defect etc. may be difficult to detect.
  • Genetic variation is divided into ve categories, pathogenic variant (PV), likely pathogenic variant (LPV), variant of unknown significance (VUS), likely benign variant (LBV), and benign variant (BV), according to 2015 ACMG/AMP (Genet Med 2015;17:405-24).
  • Likely benign variant (LBV) and Benign variant (BV) are not reported. However, the interpretation of the variation could be changed as additional evidence builds up after the results are reported.

Verifying more specific details about the Test

Link to Product